1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
1cBio has struck a regional licensing deal with Hong Kong-based Lee’s Pharmaceutical Holdings to advance OC-3, its next-generation selective PARP1 inhibitor, across Greater China and parts of Southeast Asia. Under the agreement announced September 9,…
HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion
China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could…
Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…
DualityBio Partners with Genentech in $1B-Plus Next-Generation ADC Collaboration Built Around Novel Payload Platform
China’s Duality Biotherapeutics has signed a global research, development and licensing agreement with Roche’s Genentech to develop a new generation of antibody-drug conjugates designed to overcome resistance to payloads used in today’s…
Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than…
Bio-Thera and Avalon Pharma Sign MENA Deal for BAT2406, Proposed Dupixent Biosimilar
China’s Bio-Thera Solutions and Saudi Arabia-based Avalon Pharma have entered into commercialization and license agreements for BAT2406, a proposed biosimilar to Dupixent® (dupilumab), covering Saudi Arabia and the broader Middle East and North Africa…
Henlius Expands Sandoz Partnership in Up to $322 Million Biosimilars Deal
Shanghai Henlius Biotech, Inc. (“Henlius”) has significantly expanded its partnership with Sandoz, entering a strategic collaboration covering up to 10 monoclonal antibody (mAb) and antibody-drug conjugate (ADC) biosimilar candidates in a…
Merck and InventisBio Ink a Partnership to Advance Clinical Development of Small-Molecule Cancer Drugs
August 10, 2026, Merck R&D (China) Co., Ltd. and InventisBio Co., Ltd. (or InventisBio), an innovative pharmaceutical company listed on the Science and Technology Innovation Board, simultaneously announced that they had signed a cooperation agreement…
BeiGene and Revolution Medicines Enter Strategic Collaboration
On August 10, BeiGene announced a multi-faceted collaboration agreement with Revolution Medicines. Under the agreement, the two companies will collaborate on clinical trials to jointly evaluate combination therapies of some of BeiGene’s…
CSPC and AstraZeneca Joint Venture: A New Logic for MNCs to “Build Factories” in China
A British pharmaceutical giant has decided to build its most advanced production line in Shijiazhuang, a second-tier city on the North China Plain. On August 5, AstraZeneca and CSPC Pharmaceutical Group (or CSPC) signed an agreement to establish a joint…